tiprankstipranks
Reneo Pharmaceuticals (RPHM)
NASDAQ:RPHM
US Market

Reneo Pharmaceuticals (RPHM) Income Statement

226 Followers

Reneo Pharmaceuticals Income Statement

Last quarter (Q1 2024), Reneo Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Reneo Pharmaceuticals's net income was $-8.43M. See Reneo Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 67.61M$ 83.05M$ 53.85M$ -39.82M$ 19.55M$ 15.47M
Operating Income
$ -67.61M$ -83.05M$ -53.85M$ -39.82M$ -19.55M$ -15.47M
Net Non Operating Interest Income Expense
----$ 87.00K$ 456.00K
Other Income Expense
$ -5.35M$ -5.67M$ -1.89M$ -48.00K$ 87.00K$ 2.58M
Pretax Income
$ -62.26M$ -77.39M$ -51.95M$ -39.77M$ -19.46M$ -12.44M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -62.23M$ -77.39M$ -51.95M$ -39.77M$ -19.46M$ -12.44M
Basic EPS
$ -2.07$ -2.52$ -2.12$ -2.19$ -2.50$ -1.60
Diluted EPS
$ -2.07$ -2.52$ -2.12$ -2.19$ -2.50$ -1.60
Basic Average Shares
$ 122.48M$ 30.68M$ 24.50M$ 18.14M$ 7.79M$ 7.79M
Diluted Average Shares
$ 122.48M$ 30.68M$ 24.50M$ 18.14M$ 7.79M$ 7.79M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 67.61M$ 83.05M$ 53.85M$ -39.82M$ 19.55M$ 15.47M
Net Income From Continuing And Discontinued Operation
$ -62.22M$ -77.39M$ -52.00M$ -39.77M$ -19.46M$ -12.44M
Normalized Income
$ -15.43M-$ -41.04M-$ -19.46M$ -12.44M
Interest Expense
------
EBIT
$ -65.09M$ -77.39M$ -51.95M$ -39.77M$ -19.55M$ -15.47M
EBITDA
$ -66.72M$ -77.22M$ -52.24M$ -39.52M$ -19.52M$ -15.44M
Currency in USD

Reneo Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis